OXFORD, England, March 20 /PRNewswire/ -- PharmaVentures today announces the publication of its new report on the flu epidemic, Spotlight on Influenza: Separating Fact from Fiction in the Battle against Influenza.
“The influenza virus is an interestingly unstable pathogen with global prominence. Influenza sweeps rapidly around the world in seasonal epidemics affecting 5-15% of the population and causing up to half a million deaths annually,” said Dr Fintan Walton, CEO of PharmaVentures. “Recent fears have focused on the potential threat to humans posed by the avian influenza subtype H5N1. Our new report offers a topical insight into both the flu virus and the methods being employed to tackle it.”
In particular, the report looks at the pharmaceutical industry’s pipeline prospects in the influenza field and discusses potential new treatments and vaccines in development, while simultaneously assessing their potential marketing position and value. As well as probing the industry’s ongoing investigative efforts, the report also broadly analyses and outlines the current markets, including therapeutic products.
Looking to the future, the ramifications of the H5N1 pandemic threat and its potential long-term repercussions will be reviewed from a global healthcare and commercial market perspective. The report also covers deal making and licensing opportunities, which have stemmed from the flu threat, providing an analysis of the companies, including GlaxoSmithKline, sanofi-pasteur and Chiron, as well as therapies involved, such as Tamiflu and Relenza. Background on the history of the flu, details of the different strains, including H5N1, and viral targets for therapeutic intervention will be described in detail as a key contextualising element of this report.
This topical report provides readers with insightful competitor intelligence and extended market analysis compiled from PharmaDeals(R), the most comprehensive source of global deals across all therapies and stages of development.
The summary and content of the report can be viewed at: http://www.pharmaventures.com/pdf/contents_flu_spotlight.pdf
PharmaVentures is a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with our clients to drive greater value from their deals. Based in Oxford, UK the company employs over 30 people and has offices in the USA.
PharmaVentures Ltd
CONTACT: Sarah O’Connell, Product Manager, PharmaVentures, Tel:+44-(0)-1865-784-177, Fax: +44-(0)-1865-784-178, E-mail:enquiries@pharmaventures.com, Web: www.pharmaventures.com
